Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological standardization of Dermatophagoides pteronyssinus allergen extract in HEP
2012-001939-31Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Nov 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dermatophagoides pteronyssinus in house dust mite allergy and inhalant allergy, sponsored by LETI Pharma. Started Nov 2012; status: completed.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
house dust mite allergyinhalant allergy
Beyond the preview
Go deeper on 2012-001939-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001939-31.